Mercados españoles cerrados

Pharma Mar, S.A. (PHM.MC)

MCE - MCE Precio demorado. Divisa en EUR
Añadir a la lista de favoritos
28,74+0,18 (+0,63%)
Al cierre: 05:35PM CET

Pharma Mar, S.A.

Avenida de los Reyes, 1
Pol. Industrial La Mina – Norte Colmenar Viejo
Madrid 28770
Spain
34 91 846 60 00
https://www.pharmamar.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo509

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Jose Maria Fernandez Sousa-Faro Ph.D.Founder, Executive Chairman, CEO & President294kN/AN/A
Mr. Pedro Francisco Fernandez PuentesExecutive Director124kN/AN/A
Mr. Juan Carlos-Torres CarreteroFounderN/AN/A1949
Ms. María Luisa de Francia CaballeroChief Financial OfficerN/AN/AN/A
Mr. José Luis Moreno Martinez-LosaDirector of Capital Markets & Investor RelationsN/AN/AN/A
Mr. Juan Gomez PulidoGeneral Counsel & Secretary of the Board of DirectorsN/AN/AN/A
Ms. Sandra Llamera SanchezGlobal Compliance HeadN/AN/AN/A
Ms. Lara VadilloCommunication DirectorN/AN/AN/A
Ms. Belén Sopesén Veramendi Ph.D.Director of Corporate DevelopmentN/AN/AN/A
Mr. Luis Rupérez CuencaDirector of Human Resources & ITN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2015 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14, which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trial for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trial for treating solid tumors; Tivanisiran, which is in Phase III clinical trial for the treatment of dry eye disease; and SYL1801 that is in phase II clinical trial for treating macular degeneration. In addition, it engages in the development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

Gobierno corporativo

El ISS Governance QualityScore de Pharma Mar, S.A., a día 1 de marzo de 2024, es 7. Las puntuaciones base son Auditoría: 3; Tablero: 10; Derechos de los accionistas: 7; Compensación: 5.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.